# Point of use detection of low-quality pharmaceutical asparaginase

> **NIH NIH U01** · UNIVERSITY OF NOTRE DAME · 2024 · $156,500

## Abstract

Project Summary/Abstract:
This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-
CA-24-039. Lieberman is the PI of NIH 1U01CA269195, titled “Adapting a point of use test card, the
chemoPAD, for protecting chemotherapy drug quality in sub-Saharan Africa,” which is an Affordable
Cancer Technologies (ACTs) project. Champion is an investigator not named as personnel on the parent
award who brings unique expertise in LCMS of proteins required for the proposed project. We are
requesting an administrative supplement to develop tandem MS and colorimetric screening methods for
L-asparaginase, a biological chemotherapy product that has been the subject of numerous quality
concerns in the past 5 years.

## Key facts

- **NIH application ID:** 11093733
- **Project number:** 3U01CA269195-03S1
- **Recipient organization:** UNIVERSITY OF NOTRE DAME
- **Principal Investigator:** Marya Lieberman
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $156,500
- **Award type:** 3
- **Project period:** 2022-08-23 → 2027-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11093733

## Citation

> US National Institutes of Health, RePORTER application 11093733, Point of use detection of low-quality pharmaceutical asparaginase (3U01CA269195-03S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11093733. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*